{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:00:03Z","timestamp":1794711603329,"version":"4.9.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2024-00439675"],"award-info":[{"award-number":["RS-2024-00439675"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-24536373"],"award-info":[{"award-number":["RS-2025-24536373"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022930","name":"Korea Foundation for Women In Science, Engineering and Technology","doi-asserted-by":"publisher","award":["WISET 2024-764"],"award-info":[{"award-number":["WISET 2024-764"]}],"id":[{"id":"10.13039\/100022930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25488918"],"award-info":[{"award-number":["RS-2026-25488918"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02219306"],"award-info":[{"award-number":["RS-2025-02219306"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00440778"],"award-info":[{"award-number":["RS-2024-00440778"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00332454"],"award-info":[{"award-number":["RS-2024-00332454"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00209833"],"award-info":[{"award-number":["RS-2023-00209833"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02214081"],"award-info":[{"award-number":["RS-2025-02214081"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xcrm.2026.102850","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:48:13Z","timestamp":1781189293000},"page":"102850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma"],"prefix":"10.1016","volume":"7","author":[{"given":"Jisu","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghee","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hoon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyounji","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoewon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arim","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younsoo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-woo","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejeong","family":"Youk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeongbeom","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Min","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Su","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk-Jin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungtae","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam-Shik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-2541","authenticated-orcid":false,"given":"Ki-Jun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102850_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.xcrm.2026.102850_bib3","first-page":"299","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102850_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/nox144","article-title":"Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma","volume":"20","author":"Mandel","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-024-01519-4","article-title":"Novel Clinical Trials and Approaches in the Management of Glioblastoma","volume":"26","author":"Valerius","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.xcrm.2026.102850_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae Insights: Central Nervous System Cancers, Version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.xcrm.2026.102850_bib9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102850_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.semcancer.2018.06.005","article-title":"Patient-derived tumor organoids for prediction of cancer treatment response","volume":"53","author":"Nagle","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.xcrm.2026.102850_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2017.307","article-title":"The Generation and Application of Patient-Derived Xenograft Model for Cancer Research","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2026.102850_bib13","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1158\/0008-5472.CAN-17-0582","article-title":"PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models","volume":"77","author":"Meehan","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102850_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102850_bib15","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102850_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-022-01617-6","article-title":"A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions","volume":"21","author":"Donzelli","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-023-01901-z","article-title":"Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma","volume":"23","author":"Fang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib18","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41591-019-0584-2","article-title":"A rectal cancer organoid platform to study individual responses to chemoradiation","volume":"25","author":"Ganesh","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102850_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-023-01919-3","article-title":"Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold","volume":"23","author":"Schm\u00e4che","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib21","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/1878-0261.13144","article-title":"Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer","volume":"16","author":"Cho","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib22","article-title":"Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study","volume":"4","author":"Wang","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102850_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102850_bib24","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102850_bib25","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","article-title":"Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102850_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.stem.2008.09.002","article-title":"Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals","volume":"3","author":"Eiraku","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102850_bib27","doi-asserted-by":"crossref","first-page":"20284","DOI":"10.1073\/pnas.1315710110","article-title":"Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex","volume":"110","author":"Kadoshima","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102850_bib28","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-15-2402","article-title":"A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo","volume":"76","author":"Hubert","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102850_bib29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102850_bib30","article-title":"Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors","volume":"12","author":"Chen","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102850_bib31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jocn.2020.04.107","article-title":"Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy?","volume":"78","author":"Loong","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.xcrm.2026.102850_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101251","article-title":"Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma","volume":"15","author":"Sundar","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib33","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","article-title":"Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing","volume":"15","author":"Jacob","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102850_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6605712","article-title":"Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide","volume":"103","author":"van Nifterik","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib36","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1038\/s41598-017-05931-8","article-title":"Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells","volume":"7","author":"Fujikawa","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102850_bib37","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.3390\/ijms20163982","article-title":"Exosomal L1CAM Stimulates Glioblastoma Cell Motility, Proliferation, and Invasiveness","volume":"20","author":"Pace","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102850_bib38","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.3390\/cancers13225818","article-title":"Tau Regulates Glioblastoma Progression, 3D Cell Organization, Growth and Migration via the PI3K-AKT Axis","volume":"13","author":"Pagano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102850_bib39","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.3390\/cells11142128","article-title":"The Glycoprotein M6a Is Associated with Invasiveness and Radioresistance of Glioblastoma Stem Cells","volume":"11","author":"Lacore","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2026.102850_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","article-title":"Cancer hallmarks intersect with neuroscience in the tumor microenvironment","volume":"41","author":"Hanahan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102850_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0006-2952(03)00510-0","article-title":"DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling","volume":"66","author":"Kaina","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102850_bib43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102850_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102850_bib46","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2024.01.011","article-title":"Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial","volume":"118","author":"Derby","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.xcrm.2026.102850_bib47","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","volume":"22","author":"Hanna","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-019-5413-y","article-title":"Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol","volume":"19","author":"Lesueur","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib49","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib50","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.xcrm.2026.102850_bib51","article-title":"Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity","volume":"5","author":"Verduin","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.xcrm.2026.102850_bib52","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/neuonc\/noaf007","article-title":"Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology","volume":"27","author":"Deligne","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110604","article-title":"Patient-derived tumor organoids mimic treatment-induced DNA damage response in glioblastoma","volume":"27","author":"Majc","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2026.102850_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/neuonc\/noae184","article-title":"Brain tumoroids: Treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models","volume":"27","author":"Soub\u00e9ran","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ccell.2023.12.015","article-title":"Integrated proteogenomic characterization of glioblastoma evolution","volume":"42","author":"Kim","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102850_bib56","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102850_bib57","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/s41598-023-29065-2","article-title":"Tumor organoid biobank-new platform for medical research","volume":"13","author":"Xie","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102850_bib58","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1186\/s12885-021-08972-5","article-title":"Temozolomide sensitivity of malignant glioma cell lines \u2013 a systematic review assessing consistencies between in vitro studies","volume":"21","author":"Poon","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib59","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.stem.2025.01.002","article-title":"Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy","volume":"32","author":"Peng","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102850_bib60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","article-title":"Phase II trial of gefitinib in recurrent glioblastoma","volume":"22","author":"Rich","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","article-title":"Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo\/North Central Cancer Treatment Group Study N0074","volume":"80","author":"Uhm","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.xcrm.2026.102850_bib65","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102850_bib66","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows\u2013Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102850_bib67","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102850_bib68","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/bioinformatics\/btx699","article-title":"Mosdepth: quick coverage calculation for genomes and exomes","volume":"34","author":"Pedersen","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102850_bib69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl Variant Effect Predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102850_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.xcrm.2026.102850_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","article-title":"DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102850_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102850_bib73","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102850_bib74","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102850_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102850_bib76","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102850_bib77","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nbt.3820","article-title":"Nextflow enables reproducible computational workflows","volume":"35","author":"Di Tommaso","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102850_bib78","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102850_bib79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102850_bib80","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.xcrm.2026.102850_bib81","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.omto.2022.02.006","article-title":"Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo","volume":"24","author":"Fan","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102850_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pbc.24697","article-title":"Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors","volume":"61","author":"Norris","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib83","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/etm.2022.11493","article-title":"An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia","volume":"24","author":"Sadick","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.xcrm.2026.102850_bib84","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41416-020-0905-8","article-title":"Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS\/MAPK, PI3K\/Akt\/mTOR and Fos\/Jun pathways","volume":"123","author":"Subramonian","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102850_bib85","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1111\/cas.15141","article-title":"Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance","volume":"112","author":"Yamamuro","year":"2021","journal-title":"Cancer Sci."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:06:54Z","timestamp":1784646414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666379126002673"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102850","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102850"}}